Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

NCT06837077 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia and Hyperlipidemia

Interventions

DRUG: SHR-1209 single-site subcutaneous injection
DRUG: SHR-1209 multiple-site subcutaneous injections

Sponsor

Jiangsu HengRui Medicine Co., Ltd.